GREENWICH, Conn., April 12 /PRNewswire/ -- Mederi Therapeutics Inc. announces the US release of the Stretta System for treatment of GERD. Stretta Therapy is a minimally invasive procedure that treats a debilitating condition that affects tens of millions of Americans. Stretta Therapy delivers radiofrequency (RF) energy to the muscles of the Lower Esophageal Sphincter (LES), the valve that separates the stomach from the esophagus. Stretta tightens and restores the function of this valve, which in turn reduces or eliminates regurgitation and acid exposure to the esophagus, thus reducing a patient's symptoms of GERD.
"Up to 20 percent of the population does not respond to available medications for GERD. Others have failed to get relief from surgery. In these and other properly selected patients, Stretta offers an effective, minimally invasive alternative," said Mederi CEO, Will Rutan. "GERD has a significantly negative impact on sufferer's quality of life. Stretta offers a much needed minimally invasive bridge between medications and invasive surgery."
Stretta therapy is an outpatient (same day) procedure. Patients go home shortly after the procedure and typically resume normal activities within several days. Stretta clinical studies show a 90 percent patient satisfaction score. Further, recent clinical studies have demonstrated symptom relief lasting at least 4 years.
Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.
Contact: Sheila Doyle Manager of Communications and Marketing 203 930 9980
SOURCE Mederi Therapeutics Inc.